Sign In
Buy CRL
$179.87
+5.08 (+2.91%)
At Close: Jun 03, 2026
Charles River (CRL) Advances CDMO Portfolio With Latest Offer
09:58am, Tuesday, 14'th Mar 2023
Charles River's (CRL) newest addition, pHelper plasmid, targets simplifying the complex supply chains and cutting production timelines.
Charles River (CRL) Hurt by NHP Shipment Issue, FX Woes
12:58pm, Monday, 13'th Mar 2023
The investigation related to the current NHP supply situation is likely to result in study delays in Charles River's (CRL) Safety Assessment business.
Charles River Laboratories: Buy This Compounder After The Recent Decline
09:38am, Saturday, 25'th Feb 2023
Charles River Laboratories' fourth quarter of 2022 was its strongest quarter in the company's history. However, the company's stock dropped ~12% because of challenges the company is facing with non-hu
Charles River Laboratories International, Inc. (CRL) Q4 2022 Earnings Call Transcript
03:14pm, Wednesday, 22'nd Feb 2023
Charles River Laboratories International, Inc. (NYSE:CRL ) Q4 2022 Earnings Conference Call February 22, 2023 8:30 AM ET Company Participants Todd Spencer – Vice President-Investor Relations Jim Fos
Charles River (CRL) Q4 Earnings Top Estimates, Margins Dip
03:03pm, Wednesday, 22'nd Feb 2023
Strength across the DSA and Research Models and Services RMS business segments drove Charles River's (CRL) Q4 revenues.
Charles River Laboratories (CRL) Q4 Earnings and Revenues Beat Estimates
09:47am, Wednesday, 22'nd Feb 2023
Charles River (CRL) delivered earnings and revenue surprises of 8.36% and 5.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Charles River Dives As Monkey Investigation Hamstrings 2023 Outlook
09:38am, Wednesday, 22'nd Feb 2023
Charles River Laboratories announced a shortfall in monkey shipments on Wednesday that weighed on its 2023 outlook, and CRL stock toppled. The post Charles River Dives As Monkey Investigation Hamstrin
Charles River (CRL) Introduces Novel IgY-Based ELISA Kit
12:03pm, Tuesday, 14'th Feb 2023
Charles River's (CRL) HCP-ELISA is built on its HCP-GAPex service, enhancing the efficiency and efficacy of HCP assay development.
Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call
08:30am, Thursday, 09'th Feb 2023
WILMINGTON, Mass.
Charles River (CRL) to Report Q4 Earnings: What's in Store?
09:47am, Monday, 30'th Jan 2023
The broad-based demand and meaningful price increases in the RMS business particularly in North America are expected to have contributed to Charles River's (CRL) top line in Q4.
Final Trades: Abbvie, Goldman Sachs, Charles River & more
03:56pm, Friday, 20'th Jan 2023
The "Halftime Report" traders give their top picks to watch for the second half.
Charles River's (CRL) New CDMO Tie-Up to Boost Clinical Trials
02:18pm, Friday, 20'th Jan 2023
Charles River's (CRL) latest partnership is expected to bring a potentially curative therapy, RZ-001, to HCC patients.
Charles River (CRL) to Develop RNA-based Therapy With New Pact
12:02pm, Thursday, 19'th Jan 2023
Charles River's (CRL) new partnership will enable the clinical development of RNA-based anticancer gene therapy in liver cancer patients.
Charles River (CRL) to Advance DNA Programs With New Launch
12:48pm, Friday, 13'th Jan 2023
Charles River's (CRL) launch of the eXpDNA plasmid manufacturing platform is intended to support vaccine and advanced therapy clients through clinical trials and beyond.
Here's Why You Should Retain Charles River (CRL) Stock Now
12:21pm, Wednesday, 28'th Dec 2022
Investors are optimistic about Charles River (CRL) on robust performances across the RMS and DSA segments.
